VANCOUVER, Oct. 26 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX), a leader
in advancing novel, targeted protein toxin therapeutics for the treatment of
cancer and other proliferative diseases, announced today that it has already
received a total of approximately $5.2 million of a potential $7.7 million
from the exercise of warrants issued as a result of the two tranches of a
private placement financing dated November 4 and 17, 2005. This brings the
approximate current cash position of the Company to just over $10.0 million.
